HomeCOMMENTARY
COMMENTARY

Astellas/Daiichi Sankyo Showdown Looms as Their FLT3 Inhibitors Near Approval
(Jul.12.2018)

By Shinya Sato

The curtain is about to rise on a showdown of FLT3 inhibitors in Japan, with two major drug makers girding for the battle in the new field of treatments for acute myeloid leukemia (AML). Astellas Pharma awaits approval for gilteritinib as early as this autumn, while Daiichi Sankyo is chasing the rival with quizartinib, which it hopes will get clearance next fiscal year ...
(LOG IN FOR FULL STORY)

News Calendar